Article Text

Download PDFPDF
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
  1. Sreekumari Pushpoth1,
  2. Evripidis Sykakis2,
  3. Kinnar Merchant1,
  4. Andrew C Browning1,
  5. Rajen Gupta1,
  6. S James Talks1
  1. 1Department of Ophthalmology, The Royal Victoria Infirmary, Newcastle upon Tyne, UK
  2. 2Department of Ophthalmology, Whipps Cross University Hospital, London, UK
  1. Correspondence to S James Talks, Department of Ophthalmology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; James.Talks{at}


Aim To analyse the benefit of intravitreal ranibizumab over 4 years for patients with neovascular age-related macular degeneration (AMD).

Methods A retrospective case note review of all patients who started treatment between August 2007 and September 2009 in our unit, minimum follow-up 2 years, maximum 4 years. The main outcome measures were: numbers of patients with different levels of vision, changes in visual acuity, number of treatments and numbers remaining under follow-up.

Results 1086 eyes of 1017 patients received treatment. Numbers of patients remaining under follow-up were 892/1017 (87.71%) at 12 months, 730/1017 (71.78%) at 24 months, 468/730 (64.11%) at 36 months and 110/217 (50.69%) at48 months. The main reasons for patients no longer being under follow-up were the consequences of old age or transfer of care. 50% of patients had 6/18 or better over 4 years. Patients received on average 5.79±2.53, 9.15±3.79, 11.22±4.92 and 13.7±7.84 injections by 12, 24, 36 and 48 months, respectively.

Conclusions We suggest that the numbers of patients with a particular level of vision may best reflect the actual benefit of AMD treatment provided by a service. Long-term follow-up is required as only 72/730 (10%) had been discharged at 36 months, half of whom had good vision of greater than 60 letters. 83% and 65% of patients needed treatment in the third and fourth year. Follow-up may be for the rest of the patients’ life or at some point they may no longer be well enough to attend.

  • Macula
  • Choroid
  • Degeneration
  • Neovascularisation
  • Treatment other

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Harminder Singh Dua Arun D Singh